The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Open accessAbstract
HYPOTHESIS: The paper proposes a novel unifying hypothesis-that heart failure with preserved ejection fraction (HFpEF) arises primarily from the expansion and dysfunctional transformation of visceral adipose tissue, leading to the secretion of altered suite of signaling molecules (adipokines), which causes systemic inflammation, plasma volume expansion, and cardiac hypertrophy and fibrosis. ELEMENTS OF THE FRAMEWORK: The framework groups adipokines into 3 domains. Domain I adipokines are cardioprotective molecules but are suppressed in patients with excess adiposity. Domain II adipokines are cardioprotective molecules that are up-regulated by adiposity as a compensatory response mechanism. Domain III adipokines, whose secretion is heightened in adiposity, have proinflammatory, prohypertrophic, profibrotic, and antinatriuretic effects. HFpEF results from an adiposity-driven imbalance that promotes Domain III adipokines but suppresses Domain I adipokines, with Domain II adipokines representing an inadequate counter-regulatory response. KEY LINES OF EVIDENCE: 1) Obesity and dietary nutrient excess are the major drivers of experimental HFpEF; 2) changes in visceral adiposity and circulating adipokines are observed years before and predict the diagnosis of HFpEF (but not heart failure with a reduced ejection fraction) in the general community; 3) central obesity or visceral adiposity is present in >95% of patients with HFpEF and tracks with disease severity; 4) obesity and HFpEF exhibit striking parallelism in their molecular, pathophysiological, and clinical features; 5) characteristic changes in the adipokine profile occur in parallel in central obesity and heart failure and are correlated with disease severity; 6) adipokines have established effects on cardiac structure and function that can lead to HFpEF; 7) bariatric surgery or drug treatments for HFpEF cause shrinkage of visceral fat depots (disproportionate to changes in body weight), while simultaneously increasing Domain I adipokines and decreasing Domain III adipokines; 8) excess adiposity appears to identify patients most likely to respond to current treatments for HFpEF; and 9) experimental interventions that target only adipose tissue to selectively increase or decrease its secretion of specific adipokines cause distant effects on the heart to modulate cardiac structure and the evolution of cardiomyopathy. CONCLUSIONS: The totality of evidence suggests that HFpEF evolves-not as a heterogenous disorder related to diverse comorbidities and not as a primary disorder of cardiomyocytes-but as an adipose-driven derangement that is disseminated (through endocrine-paracrine signaling) to the heart.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationA PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230405 · Cited by 2,582
Self-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationProtection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
Metadata
- Authors
- Packer, M.
- Venue
- JACC
- Publisher
- Elsevier BV
- Published
- 2025-10
- Volume
- 86
- Issue
- 16
- Pages
- 1269-1373
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W4413855533
- Cited by
- 173
- References
- 113
- FWCI
- 109.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction. https://app.cochat.ai/papers/10.1016/j.jacc.2025.06.055
- The paper
- Packer, M. (2025). The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction. JACC. https://doi.org/10.1016/j.jacc.2025.06.055
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.